Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

59.01 -1.27 (-2.11%)
Official Closing Price Updated: 4:10 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,884,529
Open 59.84
Bid (Size) 59.08 (1)
Ask (Size) 59.14 (2)
Prev. Close 60.28
Today's Range 58.72 - 59.99
52wk Range 39.35 - 63.30
Shares Outstanding 2,222,113,553
Dividend Yield 4.07%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Friday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy. 
Via Benzinga

Performance

YTD
+3.91%
+3.91%
1 Month
+5.49%
+5.49%
3 Month
+4.85%
+4.85%
6 Month
+22.33%
+22.33%
1 Year
+12.08%
+12.08%

More News

Read More
These S&P500 stocks are gapping in today's session
Via Chartmill
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
Via Benzinga
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Co Chart Analysis
Via Talk Markets
Topics Stocks / Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Via Benzinga
US Stocks Likely To Open Higher After Monday's Selloff: TSLA Stock Rebounds From Its Worst Fall In 5 Years After Trump Backs Musk, Analyst Says 'Pullbacks Are Normal'
Via Benzinga
Topics Government
Exposures Political
Which S&P500 stocks are moving on Monday?
Via Chartmill
Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
Via Benzinga
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Healthcare Sector Trying To Bounce Back
Via Talk Markets
Topics ETFs Stocks / Equities
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' Opdivo Plus Yervoy Combo Therapy Secures European Approval For Untreated Liver Cancer Patients
Via Benzinga
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
Via Benzinga
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.